The busi­ness mod­el of End­points News — and why you should sub­scribe

Pisa, Italy – 2008
From the pub­lish­er

Our busi­ness mod­el is ex­pand­ing to­day. In short: you can keep read­ing us for free, but we’re adding new ben­e­fits with paid sub­scrip­tions, and not tak­ing any con­tent away. We re­main com­mit­ted to ac­ces­si­ble jour­nal­ism.  But we plan on grow­ing the group at End­points, and we’d like your sup­port for that. So we’re ask­ing read­ers — both com­pa­nies and in­di­vid­u­als — to pur­chase one of two new sub­scrip­tion prod­ucts.

Up­grade my sub­scrip­tion now

In­di­vid­u­als

In­sid­er $200/yr

Ben­e­fits No email ads, print to PDF, ex­clu­sive opin­ion con­tent, sup­port our growth and be amongst the ear­li­est adopters of our in­de­pen­dent jour­nal­ism mod­el.

Com­pa­nies (all sizes)

En­ter­prise $1,000/yr

Li­cense Un­lim­it­ed cut-and-paste and reprint rights; pri­vate news­feed for com­pa­ny re­broad­cast, print to PDF, and ex­clu­sive opin­ion con­tent. The best way a com­pa­ny can sup­port End­points News. One li­cense cov­ers every em­ploy­ee no mat­ter how large or small the firm.


For over a year now, co-founder John Car­roll and I have been build­ing a busi­ness news com­pa­ny on an open mod­el be­cause we be­lieve the news ought to be free, ac­ces­si­ble, and eas­i­ly dis­cov­er­able by the right au­di­ences. Our job is to cre­ate a news­feed which bio­phar­ma read­ers seek out and will­ing­ly re­turn to.

We think 60% of you will not, un­der any cir­cum­stance, pay for con­tent. And that’s no prob­lem. We wel­come you, and noth­ing much will change.

Free sub­scribers will con­tin­ue get­ting full-fi­deli­ty Ear­ly Edi­tion and Fea­ture Edi­tion dai­ly email newslet­ters, plus up to four spon­sored emails per month, and en­joy one-click reg­is­tra­tion ac­cess to spe­cial re­ports and deep dives. This is all sup­port­ed by email mar­ket­ing cam­paigns from spon­sors who part­ner with us di­rect­ly to show you rel­e­vant cam­paigns.

For com­pa­nies and in­di­vid­u­als who want to sup­port our work, or could use the new ben­e­fits we’re in­tro­duc­ing to­day, the In­sid­er and En­ter­prise plans are for you.

Do I/we need a sub­scrip­tion? 

(1) Do you cut-and-paste lib­er­al­ly, be­yond fair use, from our web­site and share con­tent with col­leagues or with clients?

(2) Do you for­ward our emails or ar­ti­cles to a com­pa­ny-wide dis­tri­b­u­tion?

If the an­swer is yes to ei­ther, you need an En­ter­prise Plan li­cense.

The plan is made for near­ly all busi­ness pur­pos­es and in­tents. If you work in PR, me­dia mon­i­tor­ing, or ad­ver­tis­ing, and we re­port on your clients, chances are you might want to legal­ly use our con­tent to present it in your own for­mat or medi­um. This plan is for you.

If we buy an En­ter­prise Plan, does that mean every­one in my com­pa­ny is cov­ered?

Yes. Every­one in your com­pa­ny is cov­ered if just one per­son is the hold­er of a cur­rent En­ter­prise sub­scrip­tion. If you work at Mer­ck or Lemon­ade Stand Biotech, the price is the same.

Does the En­ter­prise plan in­clude every­thing the In­sid­er has?

No. The In­sid­er plan in­cludes the ad-free ex­pe­ri­ence. En­ter­prise plans on­ly in­clude it for the ac­count hold­er, but that ben­e­fit does not ex­tend to the en­tire com­pa­ny.

Why are you do­ing sub­scrip­tions? Isn’t the spon­sored con­tent busi­ness de­cent?

Top-class brands like Catal­ent, PPD, Brack­et, in­Ven­tiv Health Con­sult­ing, and more, all got on the ground floor and part­nered with us on smart, high-im­pact cam­paigns for their brands in our first year. You will be see­ing a lot more of that in the years to come be­cause it’s a cru­cial piece of our fu­ture.

Ar­salan Arif

But the truth is, no­body can tell the fu­ture of the news busi­ness, so like any good en­ter­prise, we’re di­ver­si­fy­ing our rev­enue. And for us, there can be no bet­ter rev­enue than the kind we get di­rect­ly from our au­di­ence. Our goal is to be around for a while. Noth­ing is more im­por­tant to our fu­ture than this pro­gram.

We have a few non-ne­go­tiables. Sharp writ­ing, con­sis­ten­cy, an­swer­able on­ly to read­ers, re­li­ably de­liv­ered, pre­sent­ed clean­ly — with full fi­deli­ty in email and on the web. No tech­ni­cal lim­i­ta­tions placed on read­ers. These are our prin­ci­ples.

And all of those ideals cost re­al mon­ey. We’re aware of the mar­gin­al cost of cre­at­ing con­tent on­line to­day. It’s painful­ly and ab­solute­ly ze­ro. But we think good con­tent and ideas will win, but not with­out the di­rect sup­port of our read­ers.

We’re go­ing to keep work­ing for it every day. We hope you join us.

Up­grade my sub­scrip­tion now

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Lat­est on ul­tra-rare dis­ease ap­proval; Pos­i­tive, if mixed, signs for Bio­gen's ALS drug; Clay Sie­gall finds a new job; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. You can now nominate someone to be highlighted in this year’s special report. Details are here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

FDA spells out how can­cer drug de­vel­op­ers can use one tri­al for both ac­cel­er­at­ed and full ap­provals

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

Clay Siegall, Morphimmune CEO

Up­dat­ed: Ex-Seagen chief Clay Sie­gall emerges as CEO of pri­vate biotech

Clay Siegall will be back in the CEO seat, taking the helm of a private startup working on targeted cancer therapies.

It’s been almost a year since Siegall resigned from Seagen, the biotech he co-founded and led for more than 20 years, in the wake of domestic violence allegations by his then-wife. His eventual successor, David Epstein, sold the company to Pfizer in a $43 billion deal unveiled last week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

FDA ad­vi­sors unan­i­mous­ly rec­om­mend ac­cel­er­at­ed ap­proval for Bio­gen's ALS drug

A panel of outside advisors to the FDA unanimously recommended that the agency grant accelerated approval to Biogen’s ALS drug tofersen despite the drug failing the primary goal of its Phase III study, an endorsement that could pave a path forward for the treatment.

By a 9-0 vote, members of the Peripheral and Central Nervous System Drugs Advisory Committee said there was sufficient evidence that tofersen’s effect on a certain protein associated with ALS is reasonably likely to predict a benefit for patients. But panelists stopped short of advocating for a full approval, voting 3-5 against (with one abstention) and largely citing the failed pivotal study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

No­vo Nordisk oral semaglu­tide tri­al shows re­duc­tion in blood sug­ar, plus weight loss

Novo Nordisk is testing higher levels of its oral version of its GLP-1, semaglutide, and its type 2 diabetes trial results released today show reductions in blood sugar as well as weight loss.

In the Phase IIIb trial, Novo compared its oral semaglutide in 25 mg and 50 mg doses with the 14 mg version that’s currently the maximum approved dose. The trial looked at how the doses compared when added to a stable dose of one to three oral antidiabetic medicines in people with type 2 diabetes who were in need of an intensified treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

Ly­me vac­cine test com­ple­tion is pushed back by a year as Pfiz­er, Val­ne­va say they'll ad­just tri­al

Valneva and Pfizer have adjusted the end date for the Phase III study of their investigational Lyme disease vaccine, pushing it back by a year after issues at a contract researcher led to thousands of US patients being dropped from the test.

In a March 20 update to clinicaltrials.gov, Valneva and Pfizer moved the primary completion date on the trial, called VALOR, from the end of 2024 to the end of 2025.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Stuart Peltz, former PTC Therapeutics CEO

Stu­art Peltz re­signs as PTC Ther­a­peu­tics CEO af­ter 25 years

Stuart Peltz, the longtime CEO of PTC Therapeutics who’s led the rare disease drug developer since its founding 25 years ago, is stepping down.

Succeeding him in the top job is Matthew Klein, who joined PTC in 2019 and was promoted to chief operating officer in 2022. In a call with analysts, he said the CEO transition has been planned for “quite some time” — in fact, as part of it, he gave the company’s presentation at the JP Morgan healthcare conference earlier this year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

Bet­ter Ther­a­peu­tics cuts 35% of staff while await­ing dig­i­tal ther­a­peu­tic ap­proval

Digital therapeutics company Better Therapeutics announced on Thursday that it’s cutting 35% of its staff as it awaits FDA clearance for its first product.

The company, which launched eight years ago, is one of a growing group of companies seeking a digital alternative to traditional medicine. The space saw a record $7.5 billion in investments in 2021, according to Chris Dokomajilar at DealForma, with uses spanning ADHD, PTSD and other indications. However, private insurers have been slow to hop on board.